Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler(R) Source: Eur Respir J 2001; 17: 1332-1333 Year: 2001
Assessment of the defined daily dose for mometasone furoate dry powder inhaler in persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Effects of mometasone furoate dry powder inhaler administered once-daily in the evening on symptom control in mild to moderate asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003
The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
A superior improvement in lung function in patients with moderate persistent asthma is seen with mometasone furoate 200 μg b.i.d delivered by dry powder inhaler compared with beclomethasone dipropionate 168 μg Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003
Effects of one year of treatment with mometasone furoate metered dose inhaler (MF-MDI) on growth in children with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 378s Year: 2004
Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007
Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS) Source: Eur Respir J 2004; 24: Suppl. 48, 164s Year: 2004
Mometasone furoate delivered via Breezhaler and Twisthaler in patients with asthma Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019
The aerodynamic particle size of mometasone furoate 100 μg and 200 μg dry powder formulations Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
Comparison of mometasone furoate dry powder inhaler 400 mcg once daily in the evening with fluticasone propionate metered dose inhaler 250 mcg twice daily in asthma patients previously maintained on fluticasone propionate Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Mometasone furoate dry powder inhaler administered once-daily in the evening reduces overnight and early morning symptoms of mild to moderate asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003
Variable lipophilicity of budesonide: Comparison with fluticasone propionate, mometasone furoate, and ciclesonide Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Formoterol delivered by multi-dose dry powder inhaler (MDDPI) improves nocturnal asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005